Thu, Apr 17, 2014, 6:49 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Apr 24, 2013 4:45 PM Flag

    What if cdx-011 gets breakthrough status?

    Regardless, cldx appears to be headed to be the next pcyc.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It ought to get breakthrough status, as it appears to meet all the criterion!!! Also, plotting pcyc vs cldx since
      November, cldx has been the better stock!! I wonder what is going to happen when the Baker Bros. latch
      on to cldx- (perhaps they have already, anyone know?) That ought to really get the stock moving!!

      • 1 Reply to wrawkit
      • Wraw, Celldex is so hot even one of the largest pharmas in the world wanted to co-author an article with CLDX.
        Published April 8, 2013
        The Rockefeller University Press, doi: 10.1084/jem.20121251
        Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation
        Lillian Cohn1, Bithi Chatterjee1, Filipp Esselborn1, Anna Smed-Sörensen1,2, Norihiro Nakamura1, Cécile Chalouni1, Byoung-Chul Lee1, Richard Vandlen1, Tibor Keler3, Peter Lauer4, Dirk Brockstedt4, Ira Mellman1, and Lélia Delamarre1
        + Author Affiliations
        1Genentech, South San Francisco, CA 94080
        2Karolinska Institutet, 171 77 Solna, Sweden
        3Celldex Therapeutics Inc., Phillipsburg, NJ 08865
        4Aduro BioTech, Inc., Berkeley, CA 94710
        Abstract
        Human BDCA3+ dendritic cells (DCs), the proposed equivalent to mouse CD8α+ DCs, are widely thought to cross present antigens on MHC class I (MHCI) molecules more efficiently than other DC populations. If true, it is unclear whether this reflects specialization for cross presentation or a generally enhanced ability to present antigens on MHCI. We compared presentation by BDCA3+ DCs with BDCA1+ DCs using a quantitative approach whereby antigens were targeted to distinct intracellular compartments by receptor-mediated internalization. As expected, BDCA3+ DCs were superior at cross presentation of antigens delivered to late endosomes and lysosomes by uptake of anti-DEC205 antibody conjugated to antigen. This difference may reflect a greater efficiency of antigen escape from BDCA3+ DC lysosomes. In contrast, if antigens were delivered to early endosomes through CD40 or CD11c, BDCA1+ DCs were as efficient at cross presentation as BDCA3+ DCs. Because BDCA3+ DCs and BDCA1+ DCs were also equivalent at presenting peptides and endogenously synthesized antigens, BDCA3+ DCs are not likely to possess mechanisms for cross presentation that are specific to this subset.

    • we get up there with sgen , i would say.

 
CLDX
14.24-0.45(-3.06%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.